Down myeloid disorders: A paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis

Early Human Development

Volumn 82, Issue 12, 2006, Pages 767-773

  Vyas, Paresh ^a   Roberts, Irene ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Acute megakaryocytic leukaemia; Down Syndrome; GATA1; Transient myeloproliferative disorder

Indexed keywords

TRANSCRIPTION FACTOR GATA 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ARTICLE; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DOWN SYNDROME; EPIGENETICS; ERYTHROCYTE; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; LEUKEMOGENESIS; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MICROARRAY ANALYSIS; MYELOPROLIFERATIVE DISORDER; NEWBORN PERIOD; NONHUMAN; PRELEUKEMIA; PROTEIN FUNCTION; TRISOMY 21;

CHILD; DOWN SYNDROME; GATA1 TRANSCRIPTION FACTOR; HUMANS; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MEGAKARYOCYTES; MYELOPROLIFERATIVE DISORDERS; THROMBOPOIESIS;

EID: 33750631224     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2006.09.016     Document Type: Article

References (23)

1. Patja K., Pukkala E., Sund R., Iivanainen M., and Kaski M. Cancer incidence of persons with Down Syndrome in Finland: a population-based study. Int J Cancer 118 (2006) 1769-1772
2. Day S.M., Strauss D.J., Shavelle R.M., and Reynolds R.J. Mortality and causes of death in persons with Down Syndrome in California. Dev Med Child Neurol 47 (2005) 171-176
3. Massey G.V., Zipursky A., Chang M.N., Doyle J.J., Nasim S., Taub J.W., et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down Syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 107 (2006) 4606-4613
4. Kivivuori S.M., Rajantie J., and Siimes M.A. Peripheral blood cell counts in infants with Down's Syndrome. Clin Genet 49 (1996) 15-19
5. Webb D.K. Optimizing therapy for myeloid disorders of Down Syndrome. Br J Haematol 131 (2005) 3-7
6. Taub J.W., and Ge Y. Down Syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 44 (2005) 33-39
7. Wechsler J., Greene M., McDevitt M.A., Anastasi J., Karp J.E., Le Beau M.M., et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down Syndrome. Nat Genet 32 (2002) 148-152
8. Ahmed M., Sternberg A., Hall G., Thomas A., Smith O., O'Marcaigh A., et al. Natural history of GATA1 mutations in Down Syndrome. Blood 103 (2004) 2480-2489
9. Cantor A.B. GATA transcription factors in hematologic disease. Int J Hematol 81 (2005) 378-384
10. Kuhl C., Atzberger A., Iborra F., Nieswandt B., Porcher C., and Vyas P. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. Mol Cell Biol 25 (2005) 8592-8606
11. Vyas P., Norris F.A., Joseph R., Majerus P.W., and Orkin S.H. Inositol polyphosphate 4-phosphatase type I regulates cell growth downstream of transcription factor GATA-1. Proc Natl Acad Sci U S A 97 (2000) 13696-13701
12. Li Z., Godinho F.J., Klusmann J.H., Garriga-Canut M., Yu C., and Orkin S.H. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 37 (2005) 613-619
13. Muntean A.G., and Crispino J.D. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood 106 (2005) 1223-1231
14. Lightfoot J., Hitzler J.K., Zipursky A., Albert M., and Macgregor P.F. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down Syndrome. Leukemia 18 (2004) 1617-1623
15. Bourquin J.P., Subramanian A., Langebrake C., Reinhardt D., Bernard O., Bellerini P., et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A 103 (2006) 3339-3344
16. Rodriguez P., Bonte E., Krijgsveld J., Kolodziej K., Guyot B., Heck A., et al. GATA-1 forms distinct activating and repressive complexes in erythroid cells. EMBO J 24 (2005) 2354-2366
17. Hong W., Nakazawa M., Chen Y.Y., Kori R., Vakoc C., Rakowski C., et al. FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J 24 (2005) 2367-2378
18. Greaves M.F., Maia A.T., Wiemels J.L., and Ford A.M. Leukemia in twins: lessons in natural history. Blood 102 (2003) 2321-2333
19. Roper R.J., and Reeves R.H. Understanding the basis for Down Syndrome phenotypes PLoS. Genetics 2 (2006) e50
20. O'Doherty A., Ruf S., Mulligan C., Hildreth V., Errington M.L., Cooke S., et al. An aneuploid mouse strain carrying human chromosome 21 with Down Syndrome phenotypes. Science 309 (2005) 2033-2037
21. Hollanda L.M., Lima C.S., Cunha A.F., Aluquerque D.M., Vassallo J., Ozelo M.C., et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 38 (2006) 807-812
22. Walters D.K., Mercher T., Gu T.L., O'Hare T., Tyner J.W., Loriaux M., et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cells 10 (2006) 65-75
23. Carpenter E., Valverde-Garduno V., Sternberg A., Mitcell C., Roberts I., Vyas P., et al. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol 128 (2005) 548-551